Airway Therapeutics

Airway Therapeutics secures a **$1.9 million NIH grant** to progress its **Phase 2b/3 clinical trial** of **Zelpultide Alfa**, a biologic therapy aimed at preventing **bronchopulmonary dysplasia** in high-risk patients. The funding supports further development of the drug, which targets respiratory and inflammatory conditions. Airway Therapeutics specializes in late-stage biologic therapies for respiratory diseases.

Sep 2026PR NewswireNews article

Airway Therapeutics CEO Dr. Marc Salzberg addresses challenges in designing clinical trials for bronchopulmonary dysplasia (BPD) in preterm infants. He highlights the complexities of neonatal intensive care unit (NICU) logistics and the need for innovative approaches to generate robust evidence in this patient population. The discussion focuses on refining trial methodologies to improve outcomes for infants at risk of BPD.

May 2026XtalksNews article

Airway Therapeutics expands its Phase III trial of the compound **zelpultide alfa** to treat **bronchopulmonary dysplasia** in over 300 preterm neonates across multiple countries. The trial assesses the drug’s safety and efficacy in high-risk newborns requiring respiratory support. The multinational design aims to broaden patient enrollment and geographic representation.

Aug 2025BioXconomyNews article

Airway Therapeutics completes dose escalation in its Phase 1b trial of **zelpultide alfa (AT-100)**, a preventive treatment for very preterm infants at risk of bronchopulmonary dysplasia. The trial evaluates the drug’s safety and efficacy in this high-risk neonatal population. This milestone follows the initial testing phase and advances the therapy toward further clinical assessment.

Apr 2023BioSpaceNews article